RRoche Read More Safety concerns continue to plague Roche’s BTK inhibitor in RMS2026-04-22 Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety concerns continue…